摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-amino-4,4,4-trichloro-2-cyano-N-[5-fluoro-4-[4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]-3-pyridyl]but-2-enamide | 1613191-98-2

中文名称
——
中文别名
——
英文名称
3-amino-4,4,4-trichloro-2-cyano-N-[5-fluoro-4-[4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]-3-pyridyl]but-2-enamide
英文别名
3-Amino-4,4,4-trichloro-2-cyano-N-[5-fluoro-4-[4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]-3-pyridyl]but-2-enamide;3-amino-4,4,4-trichloro-2-cyano-N-[5-fluoro-4-[4-(4-methylpiperazine-1-carbonyl)piperidin-1-yl]pyridin-3-yl]but-2-enamide
3-amino-4,4,4-trichloro-2-cyano-N-[5-fluoro-4-[4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]-3-pyridyl]but-2-enamide化学式
CAS
1613191-98-2
化学式
C21H25Cl3FN7O2
mdl
——
分子量
532.833
InChiKey
FQCBFACGUJZKED-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    34
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    119
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20140163000A1
    公开(公告)日:2014-06-12
    The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    本发明涉及用作ATR蛋白激酶抑制剂的化合物。本发明还涉及包括本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病、失调和病况的方法;制备本发明化合物的过程;制备本发明化合物的中间体;以及在体外应用中使用化合物的方法,例如研究生物和病理现象中的激酶、由这些激酶介导的细胞内信号转导途径的研究以及新激酶抑制剂的比较评估。本发明化合物具有式I:或药学上可接受的盐,其中变量如本文所定义。此外,本发明化合物具有式I-A:或药学上可接受的盐,其中变量如本文所定义。
  • Compounds useful as inhibitors of ATR kinase
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US09340546B2
    公开(公告)日:2016-05-17
    The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    本发明涉及用作ATR蛋白激酶抑制剂的化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病、紊乱和状况的方法;制备本发明化合物的过程;用于制备本发明化合物的中间体;以及在体外应用中使用化合物的方法,例如研究生物和病理现象中的激酶、由这些激酶介导的细胞内信号转导途径的研究;以及新的激酶抑制剂的比较评估。本发明的化合物具有公式I:或药学上可接受的盐,其中变量如本文所定义。此外,本发明的化合物具有公式I-A:或药学上可接受的盐,其中变量如本文所定义。
  • [EN] COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE<br/>[FR] COMPOSÉS UTILES EN TANT QU'INHIBITEURS D'ATR KINASE
    申请人:VERTEX PHARMA
    公开号:WO2014089379A9
    公开(公告)日:2015-01-15
查看更多